Future Program: Resuscitation and Prevention of Ischemia-Induced Dysfunction (RAPIID)

The Defense Advanced Research Projects Agency’s Biological Technologies Office is preparing to launch the Resuscitation and Prevention of Ischemia-Induced Dysfunction (RAPIID) program, a three-year initiative aimed at developing a shelf-stable, biosynthetic blood analog system for use in military trauma and hemorrhage scenarios. This pre-solicitation notice, issued as DARPA-SN-26-77, outlines the program’s core objectives: creating functional oxygen carriers, synthetic plasma substitutes, platelet-like particles, and field-deployable delivery systems such as pre-filled syringes or IV bags, along with point-of-care diagnostics and clinical guidelines. The program is structured in two phases—Phase 1 lasting 12 months to demonstrate technical viability and regulatory strategy, followed by Phase 2 spanning 24 months to advance toward clinical trials, manufacturing scale-up, and commercialization readiness for DoD acquisition. Proposals must meet a minimum Technology Readiness Level (TRL) and Manufacturing Readiness Level (MRL) of 3–4 at time of submission, with clear pathways for advancement throughout the program. All responses must be submitted via SAM.gov once the formal solicitation is posted, with the pre-solicitation response deadline set for May 19, 2026, though the actual proposal submission window will be defined in the upcoming official notice. Technical merit, innovation, regulatory feasibility, and alignment with RAPIID’s phased goals will serve as the primary evaluation criteria, with an emphasis on scalable solutions and commercialization potential rather than cost alone. The contracting office is located in Arlington, VA, with LCDR Robert Murray designated as the sole technical point of contact for inquiries; no payment, contracting officer, or inspection details are yet provided. While packaging and labeling requirements are implied to support DoD logistics standards, no specific MIL-STD or GS1 specifications are detailed. No socioeconomic set-asides, size requirements, or security clearance mandates are stated, and classified material is explicitly prohibited. Offerors must prepare for standard federal acquisition compliance, including UEI and CAGE code registration, though formal contract clauses, evaluation weights, and acceptance criteria will only be available in the full solicitation to be released on SAM.gov.